MiNK Therapeutics
INKT
21 hedge funds and large institutions have $565K invested in MiNK Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0.01% less ownership
Funds ownership: 0.21% → 0.2% (-0.01%)
11% less capital invested
Capital invested by funds: $632K → $565K (-$67.4K)
13% less funds holding
Funds holding: 24 → 21 (-3)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$932 |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$252 |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$170 |
| 4 |
JP Morgan Chase
New York
|
+$136 |
| 5 |
BlackRock
New York
|
+$102 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$11.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.95K |
| 3 |
Renaissance Technologies
New York
|
-$3.39K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.29K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.27K |
INKT Hedge Fund Activity: Q4 2024 in Review
21 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2024, worth a combined $565K — down 11% from $632K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of INKT and 1 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $932. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $11.5K sold.
- 21 institutional investors held MiNK Therapeutics (INKT) as of Q4 2024, down from 24 in Q3 2024.
- Funds reported $565K of MiNK Therapeutics stock for Q4 2024, down 11% quarter-over-quarter.
- 1 fund opened new MiNK Therapeutics positions in Q4 2024 and 4 closed out, a net change of -3 holders.
- The largest MiNK Therapeutics buyer in Q4 2024 was Tower Research Capital (TRC), an estimated $932 added.
- The largest MiNK Therapeutics seller in Q4 2024 was CAPTRUST Financial Advisors, an estimated $11.5K sold.
Based on aggregated 13F filings for Q4 2024.